达格列净联合沙库巴曲缬沙坦钠治疗急性心肌梗死患者急诊经皮冠状动脉介入治疗术后心力衰竭的临床疗效OA

Objective To explore the clinical efficacy of daglizin combined with sacubactril valsartan sodium in the treatment of heart failure after emergency percutaneous coronary intervention(PCI)in patients with acute myocardial infarction(AMI).Methods A total of 107 patients with AMI who underwent PCI and developed heart failure after surgery in the Department of Cardiology,Beihai Second People's Hospital from January 2022 to January 2023 were selected as the study objects,and were divided into control group(n=54)and observation group(n=53)according to random number table method.The control group was given sakubactril and valsartan sodium orally,and the observation group was given dagaglizin combined with Sakubactril and valsartan sodium.Left ventricular end-diastolic volume(LVEDV),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),N-terminal brain natriuretic peptide(NT-proBNP),6 min walking test(6MWT),major adverse cardiovascular events(MACE)and adverse reactions were compared between the two groups.Results After treatment,LVEDV,LVESD,LVEDD and NT-proBNP in the observation group were lower than those in the control group(P＜0.05),and LVEF and 6MWT were higher than those in the control group(P＜0.05).The incidence of MACE in observation group was lower than that in control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment of dagliagrazin combined with sackubactril valsartan sodium can effectively improve the cardiac function and reduce the risk of MACE in patients with heart failure after AMI emergency PCI,and the effect is better than that of sackubactril valsartan sodium alone.